DHANUKA Laboratories Ltd has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dhanuka Laboratories Limited (DLL), the promoter of Orchid Pharma Limited, has submitted a nil declaration under Regulation 31(4) of SEBI's Takeover Regulations for Financial Year 2025-26. The filing confirms that DLL and persons acting in concert have not created any new share encumbrances (pledges) during the year, other than those already disclosed previously. This is a routine compliance disclosure where the promoter confirms no change in pledged shareholding status.
No immediate impact on Orchid Pharma shareholders as this is a nil return confirming no new pledge creation. This regulatory filing maintains transparency about promoter-level share encumbrances and is broadly neutral for investors.